Distribution of total net revenues

SEK million

2018

Jan-Mar

2017

Jan-Mar

12 MTH

Apr 2017-

Mar 2018

12 MTH

Apr 2016-

Mar 2017

Zubsolv® US

131.1

114.1

502.8

497.5

Zubsolv – Rest of the World

-

-

5.6

65.9

Zubsolv – total

131.1

114.1

508.4

563.4

Abstral®royalties

5.8

8.7

110.3

100.9

Milestone payment Abstral

-

-

-

2.2

Abstral – total

5.8

8.7

110.3

103.1

Edluar® royalties

2.8

4.6

15.5

15.8

OX-CLI

-

-

21.8

-

Total

139.7

127.4

656.0

682.3

 

Key figures

EBITDA SEK million

2018

Jan-Mar

2017

Jan-Mar

2017

Jan-Dec

EBIT

-21.8

-23.2

57.4

Depreciation and amortization

5.5

5.1

20.8

EBITDA

-16.6

-18.1

78.2

 

Return on sharholder´s equity

 

 

2018

Jan-Mar

2017

Jan-Mar

2017

Jan-Dec

Sharholders´equity beginning balance

329.1

310.3

310.3

Sharholders´equity ending balance

305.4

273.3

329.1

Average sharholders´equity

317.3

291.8

319.7

Net earnings

-25.9

-34.6

23.2

Return of shareholders´equity %

-8.2

-11.9

7.3

 

Operating expenses SEK million

 

 

2018

Jan-Mar

2017

Jan-Mar

2017

Jan-Dec

Selling expenses

-43.3

-48.3

-190.5

Administrative expenses

-27.2

-26.3

-96.1

Research and development costs

-45,3

-30,3

-134,2

Other operating income and expenses

2.7

0.5

-1.1

Operating expenses

-113.1

-104.4

-421.9

 

Gross investments SEK million

 

 

2018

Jan-Mar

2017

Jan-Mar

2017

Jan-Dec

Investments in tangible fixed assets

-

0.3

1.1

Investments in intangible fixed assets

-

0.1

0.5

Gross investments

0.0

0.4

1.6

Cash flow

Cash flow

MSEK

Q1

2018

Q1

2017

12 MTH

Apr 2017– Mar 2018

12 MTH

Apr 2016– Mar 2017

Cash flow from operating activities

106.0

28.2

244.4

150.9

Investment activities

-

-0.3

-1.3

5.3

Financing activities

0.4

-59.0

-26.1

-149.6

Cash flow (excl exchange rate differences)

106.3

-31.1

197.0

6.6

Liquid funds

437.5

250.6

437.5

250.6